Clinical Trials Using Cabiralizumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Cabiralizumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-7 of 7
  • A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

    The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.
    Location: 13 locations

  • Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy in Treating Patients with Locally Advanced Unresectable Pancreatic Cancer

    This phase II trial studies the side effects and how well nivolumab, cabiralizumab, and stereotactic body radiotherapy work in treating patients with pancreatic cancer that has spread to nearby tissues or lymph nodes and is not able to be surgically removed. Immunotherapy with monoclonal antibodies, such as nivolumab and cabiralizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving nivolumab and cabiralizumab with stereotactic body radiotherapy may work better in treating patients with pancreatic cancer.
    Location: 2 locations

  • An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

    The purpose of this study is to evaluate the treatment of solid tumors with various immunotherapy combinations. The treatment will be determined based upon a broad biomarker assessment.
    Location: 2 locations

  • Nivolumab with or without BMS-986253 or Cabiralizumab for the Treatment of Advanced Liver Cancer

    This phase II trial studies how well nivolumab with or without BMS-986253 or cabiralizumab works in treating patients with liver cancer that has spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Monoclonal antibodies, such as BMS-986253 and cabiralizumab, may interfere with the ability of tumor cells to grow and spread. Giving nivolumab with BMS-986253 or cabiralizumab may work better in treating patients with liver cancer compared to nivolumab alone.
    Location: 2 locations

  • Nivolumab with or without Cabiralizumab for the Treatment of Resectable Biliary Tract Cancer

    This trial studies how well nivolumab with or without cabiralizumab works in treating patients with biliary tract cancer that can be removed by surgery (resectable). Cabiralizumab is an antibody (a type of human protein) that binds to a molecule called CSF-1R. CSF-1R is a molecule present on different types of cells in the immune system that control parts of the immune system. Antibodies that block CSF-1R can potentially prevent CSF-1R from reducing the anti-tumor responses mediated by the immune system. Nivolumab is an antibody that works by attaching to and blocking a molecule called PD-1. PD-1 is a protein that is present on different types of cells in the immune system and controls parts of the immune system by shutting it down. Antibodies that block PD-1 can potentially prevent PD-1 from shutting down the immune system, thus allowing immune cells to recognize and destroy tumor cells. Giving nivolumab with or without cabiralizumab may work better than usual treatments for biliary tract cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • APX005M, Nivolumab, and Cabiralizumab in Treating Patients with Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Cancer Who Have Progressed on Anti-PD1 / PDL-1 Therapy

    This phase I / Ib trial studies the best dose and side effects of APX005M, and how well it works in combination with nivolumab and cabiralizumab in treating patients with melanoma, non-small cell lung cancer and renal cell cancer that have spread to other places in the body and have progressed on anti-PD -1 / PD-L 1 therapy. Monoclonal antibodies, such as APX005M, nivolumab and cabiralizumab, interfere with the ability of tumor cells to grow and spread.
    Location: Yale University, New Haven, Connecticut

  • Stereotactic Body Radiation Therapy, Nivolumab, and Urelumab or Cabiralizumab in Treating Participants with Metastases in Advanced Solid Tumors

    This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with nivolumab and urelumab or cabiralizumab in treating participants with solid tumors that have spread to other places in the body (advanced). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, urelumab, and cabiralizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy, nivolumab, and urelumab or cabiralizumab may work better in treating advanced solid tumors.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois